Recent Updates — BETRF
BetterLife Pharma Inc. filed its unaudited interim financial statements for the three and six months ended July 31, 2026, reporting a net loss of CAD 2.7 million. The company closed a public offering on September 17, 2026, raising gross proceeds of $138.7 million by issuing common shares and pre-funded warrants to fund Phase 1A through Phase 2 clinical trials for its BETR-001 drug candidate. Subsequent events include the repayment or conversion dispute regarding a CAD 2 million convertible debenture held by director Dr. Steven Sangha, and the exercise of warrants generating $659,000 in proceeds. BetterLife Pharma Inc. is an emerging biotechnology company focused on developing compounds for neurological pain and viral infections.
BetterLife Pharma Inc. appointed Charles Duncan, PhD, as a director and Chair of the Audit Committee on August 31, 2026. The company granted Dr. Duncan stock options to purchase 500,000 common shares at an exercise price of $0.285, vesting quarterly over 24 months, plus an additional 125,000 options with a three-month vesting period. Between September 1 and 10, 2026, the company received gross proceeds of $127,500 from the exercise of 850,000 share purchase warrants at $0.15 per share. Proceeds will fund ongoing development of BETR-001 and working capital needs. The company also approved its Amended and Restated Long-term Incentive Plan on August 27, 2026. BetterLife Pharma Inc. is an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders.
BetterLife Pharma Inc. appointed Dr. Mahan Chehrenama, DO, as Chief Medical Officer to lead clinical development for BETR-001, a non-hallucinogenic neuroplastogen targeting migraine and headache disorders, with an Investigational New Drug application anticipated in the first quarter of 2027. The company granted Dr. Chehrenama stock options to purchase 500,000 common shares at an exercise price of $0.285, vesting quarterly over 24 months. Additionally, from August 1 to 21, 2026, the company received gross proceeds of $531,470 from the exercise of 4,564,697 share purchase warrants issued at prices between $0.10 and $0.15. The company also rescheduled its 2026 annual general meeting to October 14, 2026, and adopted new governance committee charters. BetterLife Pharma Inc. is a biotechnology company developing treatments for neurological disorders.
BetterLife Pharma Inc. announced a strategic pivot to prioritize its lead asset, BETR-001, for migraine and primary headache disorders, leveraging a clinically validated serotonergic mechanism. The company initiated the final IND-enabling GLP toxicology study with Nucro-Technics Inc., having completed FDA pre-IND meetings and GMP scale-up manufacturing without LSD starting material, targeting an Investigational New Drug application filing in 1Q 2027. During July 2026, the company raised $352,500 through warrant exercises ($335,000) and stock option exercises ($17,500), while converting $76,361.65 in convertible debentures into units. The board appointed John W. LaRocca as a director and audit committee member, granting him 500,000 stock options at $0.19 per share. BetterLife Pharma Inc. is a biotechnology company engaged in the development of treatments for neurological disorders.